Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours
- PMID: 9361957
- DOI: 10.2165/00003495-199700544-00005
Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours
Abstract
Polyethylene glycol (PEG)-coated (pegylated; Stealth) liposomes are stable, long-circulating drug carriers useful for delivering doxorubicin to the sites of solid tumours. Compared with conventional liposomes, pegylated liposomes are less extensively taken up by cells of the reticuloendothelial system (RES) and have a reduced tendency to leak drug while in circulation. The pharmacokinetics of PEG-liposome encapsulated doxorubicin are characterised by an extremely long circulating half-life, slow plasma clearance and a reduced volume of distribution compared with conventional liposomal doxorubicin or free doxorubicin. The long circulation and ability of pegylated liposomes to extravasate through 'leaky' tumour vasculature results in localisation of doxorubicin in tumour tissue. In a number of animal and human tumours, including breast, prostate, pancreatic and ovarian xenografts, pegylated liposomal doxorubicin produced higher intratumoural drug concentrations and better therapeutic responses than equivalent doses of conventional (nonpegylated)-liposome encapsulated doxorubicin or free doxorubicin. Low peak plasma concentrations of free doxorubicin after administration of pegylated liposomal doxorubicin and the reduced tendency of the liposomal drug to accumulate in myocardium suggest that a reduction in cardiac toxicity compared with free doxorubicin may be observed. Thus, the rationale for the use of pegylated liposomal doxorubicin in solid tumours may be summarised as follows: change in the toxicity profile with a decrease in acute adverse effects (such as nausea and vomiting) and reduced incidence of alopecia, greater activity in highly angiogenic tumours (such as Kaposi's sarcoma) and effective treatment of tumours moderately sensitive to doxorubicin (such as breast and ovarian carcinomas), with the possibility of increased tumour response because of enhanced drug accumulation. In addition, although no comparative study yet exists, there is a suggestion from early human studies with pegylated liposomal doxorubicin that cardiotoxicity may be reduced compared with the free drug.
Similar articles
-
Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.Clin Pharmacokinet. 2003;42(5):419-36. doi: 10.2165/00003088-200342050-00002. Clin Pharmacokinet. 2003. PMID: 12739982 Review.
-
Safety aspects of pegylated liposomal doxorubicin in patients with cancer.Drugs. 1997;54 Suppl 4:30-5. doi: 10.2165/00003495-199700544-00007. Drugs. 1997. PMID: 9361959 Review.
-
Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.Drugs. 1997 Mar;53(3):520-38. doi: 10.2165/00003495-199753030-00011. Drugs. 1997. PMID: 9074848 Review.
-
Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma.J Clin Pharmacol. 1996 Jan;36(1):55-63. doi: 10.1002/j.1552-4604.1996.tb04152.x. J Clin Pharmacol. 1996. PMID: 8932544 Clinical Trial.
-
Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers.Drugs. 1997;54 Suppl 4:22-9. doi: 10.2165/00003495-199700544-00006. Drugs. 1997. PMID: 9361958 Review.
Cited by
-
Nanoparticle-Based Drug Delivery Systems in Inhaled Therapy: Improving Respiratory Medicine.Pharmaceuticals (Basel). 2024 Aug 12;17(8):1059. doi: 10.3390/ph17081059. Pharmaceuticals (Basel). 2024. PMID: 39204164 Free PMC article. Review.
-
A multifunctional PEGylated liposomal-encapsulated sunitinib enhancing autophagy, immunomodulation, and safety in renal cell carcinoma.J Nanobiotechnology. 2024 Jul 31;22(1):459. doi: 10.1186/s12951-024-02664-5. J Nanobiotechnology. 2024. PMID: 39085911 Free PMC article.
-
Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer.Molecules. 2024 Feb 29;29(5):1076. doi: 10.3390/molecules29051076. Molecules. 2024. PMID: 38474590 Free PMC article. Review.
-
Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers.Small. 2023 Jul 30:e2301776. doi: 10.1002/smll.202301776. Online ahead of print. Small. 2023. PMID: 37518857 Review.
-
A detailed insight of the tumor targeting using nanocarrier drug delivery system.Drug Deliv. 2023 Dec;30(1):2183815. doi: 10.1080/10717544.2023.2183815. Drug Deliv. 2023. PMID: 36866455 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources